Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer.
Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer.
复制标题
DOI：
10.1001/archoto.2010.211
复制
发表时间：
2010-12
影响因子：
--
通讯作者：
Wolf, Gregory T.
中科院分区：
文献类型：
--
作者：
Wansom, Derrick;Light, Emily;Worden, Frank;Prince, Mark;Urba, Susan;Chepeha, Douglas B.;Cordell, Kitrina;Eisbruch, Avraham;Taylor, Jeremy;D'Silva, Nisha;Moyer, Jeffrey;Bradford, Carol R.;Kurnit, David;Kumar, Bhavna;Carey, Thomas E.;Wolf, Gregory T.
确定与人乳头瘤病毒（HPV）16阳性癌症相关的有利结果是否与患者的适应性免疫有关。学术医学中心。在一项前瞻性放化疗临床试验中，66例既往未接受治疗的患者中有47例（20例II期患者中有6例，46例IV期癌症患者中有41例）。所有患者均接受单疗程新辅助化疗，随后进行手术（对于无应答者）或同时进行化疗和常规放疗。通过流式细胞术测量CD 3、CD 4、CD 8、NK和B细胞以及总体WBC的给药前水平（百分比和绝对计数）。确定亚群与HPV-16状态、肿瘤亚部位、分期、T分类、N分类、吸烟状况、体能状况、性别、对放化疗的反应、p53突变类型、表皮生长因子受体表达以及疾病特异性和总生存率的相关性。中位随访6.6年后，生存率的提高与CD 8水平百分比升高（P= 0.04）、CD 4：CD 8比值降低（P= 0.01）、表皮生长因子受体表达降低（P= 0.002）和HPV状态（P= 0.02）相关。HPV-16阳性患者的CD 8细胞水平百分比显著较高（P= 0.04）。较高百分比的CD 8细胞与诱导化疗的应答（P=.02）和放化疗后的完全肿瘤应答（P=.045）相关。这些发现证实了先前结果与循环CD 8细胞水平的相关性，并支持了以下推测：改善的适应性免疫可能在HPV-16阳性癌症患者的良好预后中发挥作用。
To determine whether the favorable outcome associated with human papillomavirus (HPV) 16-positive cancer is related to a patient’s adaptive immunity. Academic medical center. Forty-seven of 66 previously untreated patients (6 of 20 patients with stage II and 41 of 46 with stage IV cancer) in a prospective clinical trial of chemoradiotherapy. All patients were treated with a single course of neoadjuvant chemotherapy followed by either surgery (for non-responders) or concurrent chemotherapy and conventional radiation. Pretreatment levels (percentages and absolute counts) of CD3, CD4, CD8, NK, and B cells and overall WBC were measured by flow cytometry. Correlations of subsets with HPV-16 status, tumor subsite, stage, T class, N class, smoking status, performance status, gender, response to chemoradiotherapy, p53 mutation type, epidermal growth factor receptor expression, and disease specific and overall survival were determined. After median follow up of 6.6 years, improved survival was associated with elevated percentage of CD8 levels (P=.04), a low CD4:CD8 ratio (P=.01), low epidermal growth factor receptor expression (P=.002), and HPV status (P=.02). The percentage of CD8 cell levels were significantly higher (P=.04) in HPV-16-positive patients. A higher percentage of CD8 cells was associated with response to induction chemotherapy (P=.02) and complete tumor response after chemoradiation (P=.045) These findings confirm previous correlations of outcome with circulating CD8 cell levels and support the conjecture that improved adaptive immunity may play a role in the favorable prognosis of patients with HPV-16-positive cancers.
登录
查看更多内容
DOI：
10.1073/pnas.0406904102
发表时间：
2005-05-24
影响因子：
11.1
作者：
Yang, H;Yang, K;Kurnit, DM
通讯作者：
Kurnit, DM
影响因子：
11.5
作者：
Sirianni, N;Ha, PK;Ferris, RL
通讯作者：
Ferris, RL
影响因子：
4.6
作者：
Chu, NR;Wu, HB;Mizzen, LA
通讯作者：
Mizzen, LA
影响因子：
11.5
作者：
Smith, Kent A.;Meisenburg, Brenna L.;Bot, Adrian
通讯作者：
Bot, Adrian
DOI：
10.1158/1078-0432.ccr-09-2350
发表时间：
2010-02-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Maxwell JH;Kumar B;Feng FY;Worden FP;Lee JS;Eisbruch A;Wolf GT;Prince ME;Moyer JS;Teknos TN;Chepeha DB;McHugh JB;Urba SG;Stoerker J;Walline HM;Kurnit DM;Cordell KG;Davis SJ;Ward PD;Bradford CR;Carey TE
通讯作者：
Carey TE